Henry Schein (HSIC) Stock Price, News & Analysis

Company Overview

Henry Schein, Inc. is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes. This includes practice management software, e-commerce platforms, digital imaging systems, and advanced sterilization and infection control solutions. The company also offers financial services, consulting, and supply chain management programs designed to help healthcare practices optimize inventory, reduce operating costs and comply with regulatory requirements.

Founded in 1932 by Henry Schein in Queens, New York, the company has grown from a small health products supplier into a Fortune 500 organization headquartered in Melville, New York. Over the decades, Henry Schein has expanded through strategic acquisitions and organic growth, establishing a presence in more than 30 countries and serving over one million customers worldwide. Its global logistics network and local market expertise enable rapid delivery of products and responsive support for healthcare professionals across North America, Europe, Asia Pacific, Latin America and Africa.

Under the leadership of Chairman and Chief Executive Officer Stanley M. Bergman, who joined the company in the late 1980s, Henry Schein has pursued a strategy centered on customer service excellence, innovation and partnerships. The company collaborates with manufacturers, technology developers and professional associations to introduce new solutions and best practices to the marketplace. With a commitment to sustainability and community engagement, Henry Schein continues to invest in research, education and outreach programs that support the health and well-being of practitioners and patients around the world.

Key Stats

• Today's Range: $69.81 to $73.25
• 50-Day Range: $70.50 to $82.39
• 52-Week Range: $61.94 to $89.29
• Volume: 2.95 million shs
• Average Volume: 1.26 million shs
• Market Capitalization: $8.03 billion
• P/E Ratio: 21.30
• Dividend Yield: N/A
• Price Target: $86.83
• Consensus Rating: Hold

Henry Schein Stock Analysis - MarketRank™

Henry Schein scored higher than 78% of companies evaluated by MarketBeat, and ranked 128th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Henry Schein has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on no strong buy ratings, 6 buy ratings, 7 hold ratings, and 1 sell rating.

Upside Potential

Henry Schein has a consensus price target of $86.83, representing about 23.2% upside from its current price of $70.50.

Amount of Analyst Coverage

Henry Schein has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 9.42%

Earnings Growth

Earnings for Henry Schein are expected to grow by 9.42% in the coming year, from $5.31 to $5.81 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Henry Schein is 21.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.16.

Price to Earnings Ratio vs. Sector

The P/E ratio of Henry Schein is 21.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.70.

Price to Earnings Growth Ratio

Henry Schein has a PEG Ratio of 1.82. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Henry Schein has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.73% of the float of Henry Schein has been sold short.

Short Interest Ratio / Days to Cover

Henry Schein has a short interest ratio ("days to cover") of 6.99.

Change versus previous month

Short interest in Henry Schein has recently increased by 5.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Henry Schein does not currently pay a dividend.

Dividend Growth

Henry Schein does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.55

News Sentiment

Henry Schein has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 29 news articles for Henry Schein this week, compared to 7 articles on an average week.

Search Interest

3 people have searched for HSIC on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Henry Schein to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Henry Schein insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,574,982.00 in company stock.

Percentage Held by Insiders

0.89% of the stock of Henry Schein is held by insiders.

Percentage Held by Institutions

96.62% of the stock of Henry Schein is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HSIC Stock Analysis - Frequently Asked Questions

How have HSIC shares performed this year?

Henry Schein's stock was trading at $75.58 at the start of the year. Since then, HSIC stock has decreased by 6.7% and is now trading at $70.50.

How were Henry Schein's earnings last quarter?

Henry Schein, Inc. (NASDAQ:HSIC) released its quarterly earnings data on Tuesday, May, 5th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.12. The firm's revenue was up 6.3% compared to the same quarter last year.
Read the conference call transcript.

When did Henry Schein's stock split?

Shares of Henry Schein split on the morning of Friday, September 15th 2017.The 2-1 split was announced on Wednesday, August 16th 2017. The newly created shares were distributed to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Does Henry Schein have any subsidiaries?

Henry Schein subsidiaries include these companies: Prism Medical Products LLC, Elite Computer Italia, Southern Anesthesia & Surgical, Marrodent, Dental Cremer, RxWorks, Dental Trey, and more.

Who are Henry Schein's major shareholders?

Top institutional shareholders of Henry Schein include Dimensional Fund Advisors LP (2.50%), Swedbank AB (1.14%), SG Americas Securities LLC (0.53%) and Bank of New York Mellon Corp (0.48%). Insiders that own company stock include Stanley M Bergman, James P Breslawski, Michael S Ettinger, Thomas C Popeck, Mark E Mlotek, Lorelei Mcglynn, David B Brous Jr, Bradford C Connett, Philip A Laskawy and Kurt P Kuehn.
View institutional ownership trends.

How do I buy shares of Henry Schein?

Shares of HSIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Henry Schein own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Henry Schein investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR), AUO (AUOTY) and The RMR Group (RMR).

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/07/2026
• Bank of America Global Healthcare Conference 2026: 5/13/2026
• Stifel Jaws & Paws Conference 2026: 5/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Health Care Distributors
• Current Symbol: NASDAQ:HSIC
• CIK: 1000228
• Web: www.henryschein.com
• Phone: (631) 843-5500
• Fax: 631-843-5541
• Employees: 25,000
• Year Founded: 1932

Price Target and Rating

• Average Price Target for Henry Schein: $86.83
• High Price Target: $100.00
• Low Price Target: $64.00
• Potential Upside/Downside: +23.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.36
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.27
• Trailing P/E Ratio: 21.30
• Forward P/E Ratio: 13.28
• P/E Growth: 1.82
• Net Income: $398 million
• Net Margins: 2.95%
• Pretax Margin: 4.02%
• Return on Equity: 15.44%
• Return on Assets: 5.53%

Debt

• Debt-to-Equity Ratio: 0.59
• Current Ratio: 1.36
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: $13.18 billion
• Price / Sales: 0.61
• Cash Flow: $7.57 per share
• Price / Cash Flow: 9.31
• Book Value: $34.40 per share
• Price / Book: 2.05

Miscellaneous

• Outstanding Shares: 113,920,000
• Free Float: 113,727,000
• Market Cap: $8.03 billion
• Optionable: Optionable
• Beta: 0.82